Protocols
12 protocol(s) meet the specified criteria
Disease Site: Any Site
Protocol No.TitleStatus
2843-1001A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects with Relapsed/Refractory Advanced and/or Metastatic Solid TumorsOpen
AGCT1532A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell TumorsOpen
BBI-DSP0509-101A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, in Adult Patients with Advanced Solid TumorsOpen
BP29889AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY, PART I) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN PATIENTS WITH METASTATIC SOLID TUMORSOpen
DEBIO-1347-201A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 (Study # Debio 1347-201)Open
EAY131-CIRBMolecular Analysis of Therapy Choice (MATCH)Open
EAY131-EMATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFROpen
EAY131-K1Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR AmplificationsOpen
EAY131-K2Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase 2 Study of JNJ-42756493 (Erdafitinib)in Patients with Tumors with FGFR Mutations or Fusions.Open
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
LAO-NCI-9938-CIRBPhase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumorsOpen
NANT17-01/MIBG-DA Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory NeuroblastomaOpen